Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases.
FAIL · Does not pass the screen
46.16 USD
Screen close, 2026-10-01 · not a live quote Last reviewed 4 days ago
Screened 2026-10-01 · the tape above runs as of 07:26 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 46.16 against the desk's fair-value range, base estimate 71.50, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price46.16 USD
Fair value71.50
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown46.16+0.0% to today
2026-09-13Read Accumulation55.41-16.7% to today
2026-08-13Read Markup52.64-12.3% to today
2026-07-02Read Accumulation44.18+4.5% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Scholar Rock Holding Corporation holds its Markdown at $46.16. The statistical read favours the sellers, held for 390 days.
As held on the ledger · 2026-10-01
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 390 days
Price at the screen
$46.16
Valuation
N/A trailing · -18.12 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.68
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
26.94%
Below 33%
Interest-bearing debt is just 26.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
10.89%
Below 33%
Cash held in interest-bearing accounts and securities is 10.9% of assets, under the one-third limit.
Pass
Receivables
80.72%
Below 49%
Money owed to the company is 80.7% of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Scholar Rock's business is fine, but its receivables are about 81% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-01 screen. The gold marker is the market price at the same screen. A 54.9% margin of safety to the base estimate.
Third-party analyst targets: 16 covering, consensus Strong Buy. The average target sits +55% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-01 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Rare disease biotech missing the numbers that matter
A family facing spinal muscular atrophy needs real treatments, not just hope. Scholar Rock works on molecular mechanisms that could ease neuromuscular diseases, with analysts clustered around a $58 target and our own fair value sitting only 10 percent higher than the current $52.86 price.
We pass. The ethical screen returns insufficient data because basic financial ratios are absent, and the available figures, forward P/E of minus 22.3 times, zero profit margin and return on equity of minus 139 percent, leave too many gaps for a clear verdict. Unknown moat adds to the uncertainty.
Those gaps matter in a sector where most candidates fail late trials and cash burn can stretch for years. Without reliable ratios the margin of safety stays untested, regardless of bullish consensus. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SRRK trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown · changed$46.16-16.7%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 16.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 21% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (16 analysts) rates it none, with a mean price target of $59. Since the last review it entered the Titan Ethical 500; its composite score rose.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 21% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (16 analysts) rates it none, with a mean price target of $59.
2026-08-13Markup · changed$52.64+19.1%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 19.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 21% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (16 analysts) rates it none, with a mean price target of $59.
2026-07-18Accumulation$44.18+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 21% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 28%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (16 analysts) rates it none, with a mean price target of $59.
2026-07-03Accumulation$44.18+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$44.18Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
